Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Bicycle Therapeutics headquartered in Europe, operates in the Biotechnology, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $184.5B in funding across 168 round(s). With a team of 101-250 employees, Bicycle Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Bicycle Therapeutics, raised $6.0M. Discover more about their projects, partnerships, and impact on our platform.